Allos Therapeutics News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Monday evening.

SCOTTSDALE, Ariz.-- --Hypercom Corporation , the high security electronic payment and digital transactions solutions provider, today announced financial results for the third... 11/03/2009 - 04:02 PM Fitch Rates Columbus, Ohio's $279MM GOs 'AAA' CHICAGO-- --Fitch Ratings assigns an 'AAA' rating to the City of Columbus, Ohio's general obligation ...

Colorado biotech firm Allos Therapeutics Inc. posted a bigger third-quarter loss, citing higher administrative and marketing costs as it gears up to sell its newly approved cancer drug Folotyn.

Allos Therapeutics, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management will provide a corporate update and review of the third quarter 2009 results via webcast and conference call on Tuesday, November 3, 2009, at 4:30 p.m. ET.

Allos Therapeutics Inc. has closed its previously announced public offering of 14 million shares of newly issued common stock at $7.10 per share.

14 - 15, 2009 at the Javits Convention Center in New York, NY. Content & Communications World breaking news rele... DALLAS & WALL, N.J.-- --AT&T* and Centennial Communications Corp.

Our analysts have issued complimentary analysis on the following six companies: EarthLink Inc.

Allos Therapeutics, Inc. today announced the pricing of an underwritten public offering of 14,000,000 primary shares of its common stock at a public offering price of $7.10 per share.

Several small-cap stocks were poised to move on above-average volume during Tuesday's session Extreme Networks tumbled by 38 cents, or 13.2%, to $2.49 in the premarket session after the company on late Monday said fiscal first-quarter net revenue is expected to be approximately $66 million, well below the Thomson Reuters consensus of $80.4 million.

David Gardner called it. Hea s up 1,334%! See what Davida s recommending that you buy NEXT.

Pralatrexate, a metabolic inhibitor that resembles folic acid, has been approved for the treatment of peripheral T-cell lymphoma in patients whose disease has returned or not responded to previous therapy, FDA and Allos Therapeutics Inc.

Allos Therapeutics said Friday that it has received regulatory approval for its drug to treat a rare form of blood cancer.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Even as Allos Therapeutics Inc. prepares for the commercial launch of Folotyn in relapsed, refractory peripheral T-cell lymphoma following accelerated FDA approval, the Westminster, Colo.-based firm already has its sights set on expanding the targeted antifolate drug into broader the T-cell lymphoma space and other cancer indications.

MENLO PARK, Calif., NEW YORK and BIRMINGHAM, Ala., Sept. 25 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma .

Allos Therapeutics, Inc. today announced that last night the U.S. Food and Drug Administration granted accelerated approval for FOLOTYNTM for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma .

We are awaiting the US Food and Drug Administration's decision regarding Allos Therapeutics ' lymphoma drug Folotyn.

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Tuesday evening.

The Dow opened the week down 41 points Monday, while the NASDAQ composite rose. In Colorado, Allos Therapeutics was among the few actively traded gainers, while Delta Petroleum fell 45 percent on disappointing well-test results.